Aurobindo Pharma’s arm enters into agreement with global pharma major

25 Nov 2024 Evaluate

Aurobindo Pharma’s wholly owned subsidiary-- Aurobindo Pharma USA Inc., has entered into a Collaboration and License Agreement on November 22, 2024 with a global pharma major for development of specific products across respiratory therapeutic area and their commercialisation.

Both the parties will co-exclusively commercialize the product. The products, once commercialized, will be manufactured at Partner’s facility and will be marketed by both the parties. Aurobindo has an option to technology transfer at a future date. A cost-sharing arrangement has been agreed by both the parties with each of them contributing 50% of the cost incurred with an overall cap of $90 million for Aurobindo over the development period. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1176.65 -40.80 (-3.35%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×